Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
This study is looking at how obesity might affect a woman's reproductive hormones. Researchers want to see if obese women respond differently to estradiol patches (a form of estrogen) compared to women with a normal weight. They are specifically measuring the amount of Luteinizing hormone (LH) surge, which is a key hormone in ovulation, after participants wear estradiol patches for 7 days. This study is for women aged 18 to 38 who have regular menstrual cycles. The goal is to understand if obesity causes abnormal responses in the body's hormone control centers. The study's current status is unclear, and it plans to enroll 20 participants.
- Study design
- This is an open-label study, meaning both you and the study team will know what treatment you are receiving. It involves a small group of 20 women.
- What's involved
- You would have a screening period of up to 3 weeks, followed by a treatment period of 7-10 days. During treatment, you would wear estradiol patches for up to 7 days, have one blood draw, and collect daily morning urine.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary measurement for the study is taken at the end of the 7-day treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Nanette Santoro, MD · PRINCIPAL_INVESTIGATOR · University of Colorado School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Amount of Luteinizing hormone SurgeFrom enrollment to the end of treatment is 7 days.
Urinary luteinizing hormone concentration in mIU/mg of Creatinine